Antitumor Effect of New HER2 Peptide Vaccination Based on B Cell Epitope

While the benefit of passive immunotherapy is commonly accepted, active immunization may have advantages for the patient's quality of life. We identified a new epitope of Mab CH401 against Her-2/neu extracellular domain (N: 167-175), and evaluated the effect of active immunization of the 20mer...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2011-10, Vol.31 (10), p.3361-3368
Main Authors: MIYAKO, Hirohito, KAMETANI, Yoshie, IMAI, Kohzoh, HABU, Sonoko, MAKUUCHI, Hiroyasu, TOKUDA, Yutaka, KATANO, Ikumi, ITO, Ryoji, TSUDA, Banri, FURUKAWA, Atsuko, SAITO, Yuki, ISHIKAWA, Dai, OGINO, Koichi, SASAKI, Shigeru
Format: Article
Language:English
Subjects:
Amino Acid Motifs
Amino Acid Sequence
Animals
Antibodies, Monoclonal - immunology
Antigens, Neoplasm - chemistry
Antigens, Neoplasm - immunology
Antineoplastic Agents - pharmacology
Biological and medical sciences
Cancer Vaccines - immunology
Cell Line, Tumor
Cell Proliferation - drug effects
Epitope Mapping
Epitopes, B-Lymphocyte - chemistry
Epitopes, B-Lymphocyte - immunology
Female
Humans
Lymphocyte Depletion
Medical sciences
Mice
Mice, Inbred BALB C
Molecular Sequence Data
Neoplasm Transplantation
Peptides - chemistry
Peptides - immunology
Peptides - pharmacology
Receptor, ErbB-2 - chemistry
Receptor, ErbB-2 - immunology
Tumors
Vaccination
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:While the benefit of passive immunotherapy is commonly accepted, active immunization may have advantages for the patient's quality of life. We identified a new epitope of Mab CH401 against Her-2/neu extracellular domain (N: 167-175), and evaluated the effect of active immunization of the 20mer peptide containing the epitope (CH401 peptide). Epitope-mapping was performed using ELISA with Her-2/neu-related multiple antigen peptides (MAP). BALB/c mice were transplanted with Her-2/neu-expressing lymphoma cell line and immunized with the peptides. For monitoring the condition, ELISA and flow cytometry was performed. CH401 peptide induced Her-2/neu-specific IgG antibody. Tumor growth in immunized mice was suppressed and tumor-infiltrating lymphocytes comprised more CD8(+) T-cells, which secreted larger amounts of interleukin-2 after the peptide re-stimulation. The new Her-2/neu peptide contained epitopes for CD4(+) and CD8(+) T-cells, which contributes to the suppressive effect on Her-2/neu-expressing tumor cell growth.
ISSN:0250-7005
1791-7530